Relativity Acquisition Shareholders Approve Business Combination with Instinct Bio Technical
ACQC has more than doubled off its 52-week low of $2.
Summary
Relativity Acquisition Corp. (ACQC) shareholders have approved the previously announced business combination with Instinct Bio Technical Company Inc., a vertically integrated leader in the stem cell and regenerative medicine sector. This approval is a critical milestone for the SPAC, significantly de-risking the completion of its de-SPAC transaction. The combined entity, to be named Instinct Bio Technical Company Holdings Inc., is expected to list on Nasdaq under the ticker 'BIOT' in the coming weeks. Traders should monitor the upcoming 8-K filing for full voting results and the definitive closing date of the business combination.
At the time of this announcement, ACQC was trading at $12.26 on OTC in the Life Sciences sector, with a market capitalization of approximately $52.8M. The 52-week trading range was $2.00 to $35.22. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.